HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Frugal Fatigue,” Luxury Purchases Propel Personal-Care Sales In 2011

This article was originally published in The Rose Sheet

Executive Summary

U.S. consumers are shopping with greater financial confidence and treating themselves to affordable luxuries in the personal-care category, research firm Kline & Company says. Nail products and limited-distribution fragrances had standout performances in 2011.

You may also be interested in...



Coty Growth Driven By On-Trend New Products

Marketer of Sally Hansen and Rimmel attributes its strong growth in 2011 to staying ahead of trends in the marketplace. Coty Inc. expects more of the same for 2012, along with a highly anticipated Lady Gaga scent, expected to be the “biggest fragrance launch this year.”

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts

Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018159

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel